Plant Name: Lawsonia inermis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; CXCR1; | |
| DRD4; | |
| ALPI; RECQL; TDP1; PLA2G1B; BLM; PIK3R1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; IDO1; ALOX12; NOX4; TNKS; PARP1; TNKS2; PYGL; POLB; CD38; AOX1; | |
| MGAM; GAA; | |
| CDC25B; | |
| NEK6; PKN1; AKT1; MET; MAP2K1; CSNK2A1; DAPK1; AXL; NEK2; FLT3; ABL1; CAMK2B; SRC; IGF1R; AURKB; GSK3B; CDK1; MAPK1; EGFR; PIM1; NUAK1; ALK; PTK2; KDR; | |
| CA14; CA3; CA7; CA5A; CA12; CA9; CA4; CA6; CA2; CA1; | |
| ESRRB; ESRRA; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; MAOB; XDH; | |
| MMP13; MMP12; MMP3; MMP2; MMP9; | |
| BACE1; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| DNMT1; | |
| ABCC1; ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; THPO; RAB9A; NPC1; APP; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.434E-13 | 1.358E-10 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.821E-12 | 1.410E-09 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, TBXAS1, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.916E-12 | 1.755E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, IDO1, MPO, NOX4, SRC, TBXAS1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 6.771E-11 | 1.776E-08 | ABCG2, AKT1, ALK, AOX1, APP, BLM, CAMK2B, CD38, CSNK2A1, DAPK1, DRD4, EGFR, ESR1, ESR2, FLT3, IGF1R, KDR, L3MBTL1, MAOB, MAPK1, MET, MMP9, NFKB1, PARP1, PYGL, RAB9A, SMN1, SMN2, STAT6, TP53, TTR, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.061E-10 | 2.718E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.410E-10 | 3.490E-08 | ABCC1, ABCG2, ABL1, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, FLT3, GSK3B, IGF1R, KDR, MAP2K1, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.945E-10 | 6.750E-08 | ABL1, AURKB, CA2, CA7, EGFR, HIF1A, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.906E-10 | 8.591E-08 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAP2K1, MAPK1, PKN1, TNKS |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 7.409E-10 | 1.536E-07 | ABL1, AURKB, CA2, CA7, CD38, EGFR, HIF1A, KDR, MAPK1, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, SRC, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.244E-10 | 1.617E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.063E-09 | 2.013E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.091E-09 | 3.706E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 2.975E-09 | 5.022E-07 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, GSK3B, MAP2K1, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.260E-08 | 2.911E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, TNKS |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.533E-08 | 3.207E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.187E-08 | 9.433E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.308E-07 | 1.390E-05 | AKR1B1, AOX1, CYP19A1, CYP1A2, IDO1, MAOB, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.002E-07 | 2.027E-05 | ABL1, EGFR, IGF1R, KDR, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.946E-07 | 3.656E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.946E-07 | 3.656E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 4.329E-07 | 3.969E-05 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 6.547E-07 | 5.657E-05 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 6.547E-07 | 5.657E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 9.733E-07 | 8.151E-05 | ABL1, AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.058E-06 | 8.797E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.285E-06 | 1.040E-04 | ABL1, ALOX15, APP, EGFR, KDR, MAP2K1, NOX4, SRC, THPO |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.549E-06 | 1.240E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.788E-06 | 1.421E-04 | AXL, EGFR, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.796E-06 | 1.422E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.831E-06 | 2.133E-04 | MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 2.880E-06 | 2.163E-04 | AKR1B1, AOX1, CYP19A1, CYP1A2, IDO1, MAOB, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.085E-06 | 2.269E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.085E-06 | 2.269E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 3.685E-06 | 2.666E-04 | AKT1, EGFR, MET, NEK2, PIK3R1, STAT6, TP53 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 3.769E-06 | 2.700E-04 | ABL1, AKT1, ALOX12, APP, AXL, CA2, CAMK2B, CDK1, CYP1B1, ESRRB, HIF1A, IDO1, KDR, LMNA, MAP2K1, NFKB1, PARP1, PIM1, SRC, STAT6, THPO |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 5.377E-06 | 3.723E-04 | AKT1, EGFR, ESR1 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 7.385E-06 | 4.933E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.995E-06 | 5.276E-04 | ABCC1, CA2, CA4, CA9, EGFR, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0060020; Bergmann glial cell differentiation | 8.569E-06 | 5.587E-04 | ABL1, MAP2K1, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 8.569E-06 | 5.587E-04 | CYP1A1, CYP1A2, MAOB |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 8.826E-06 | 5.737E-04 | ABL1, AKR1B1, AKT1, ALOX5, AURKB, BLM, CAMK2B, CDC25B, CDK1, CSNK2A1, DNMT1, ESR1, ESR2, ESRRA, ESRRB, GSK3B, HIF1A, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NUAK1, PARP1, PIM1, PKN1, POLB, RECQL, SMN1, SMN2, SRC, STAT6, TNKS, TP53 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.280E-05 | 7.943E-04 | BLM, RECQL, TP53 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.307E-05 | 8.037E-04 | ALK, CDK1, DRD4, MAP2K1, MAPK1, PKN1, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.314E-05 | 8.037E-04 | PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.314E-05 | 8.037E-04 | APP, GSK3B, IGF1R, PARP1 |
| BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 1.710E-05 | 1.031E-03 | AURKB, CDK1, ESR1, TNKS, TNKS2 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.802E-05 | 1.072E-03 | ABL1, CA2, CA7, KDR, NPSR1, PARP1, PLA2G1B, SRC |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.842E-05 | 1.093E-03 | ABL1, AKT1, CA5A, CDK1, CYP1A1, CYP1B1, ESR2, GSK3B, HSD17B10, MAOA, MAOB, MAP2K1, MAPK1, MMP2, MPO, NFKB1, NOX4, PARP1, SRC, TP53 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.036E-05 | 1.176E-03 | ABL1, AXL, CYP1A1, CYP1A2, IDO1, MAOB, MPO, NFKB1, SRC |
| BP | GO:0009987; cellular process | GO:0032872; regulation of stress-activated MAPK cascade | 2.286E-05 | 1.303E-03 | AKT1, APP, EGFR, IGF1R, MAP2K1, MAPK1, PKN1, XDH |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.385E-05 | 1.345E-03 | ABL1, AKT1, ALOX12, APP, AXL, CA2, CAMK2B, CDK1, CYP1B1, EGFR, ESR1, ESRRA, GSK3B, HIF1A, IDO1, KDR, L3MBTL1, MAP2K1, PIK3R1, PIM1, PTK2, SRC, STAT6, THPO, XDH |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.749E-05 | 1.535E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 2.927E-05 | 1.591E-03 | AOX1, XDH |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.927E-05 | 1.591E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.927E-05 | 1.591E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.927E-05 | 1.591E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 3.164E-05 | 1.710E-03 | ALOX15, ESR1, GSK3B, MET, MMP3, PARP1, SRC, TP53 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 3.314E-05 | 1.786E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 3.425E-05 | 1.838E-03 | AKT1, ESRRB, HIF1A, NFKB1, SRC |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 3.942E-05 | 2.074E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
| BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 4.247E-05 | 2.197E-03 | CA2, CD38, EGFR, SRC |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 4.291E-05 | 2.211E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.518E-05 | 2.321E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 4.971E-05 | 2.506E-03 | AKT1, AURKB, BLM, CSNK2A1, L3MBTL1, NUAK1, TP53 |
| BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 5.178E-05 | 2.586E-03 | APP, CA2, CA7, DRD4, EGFR, MAPK1 |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 5.439E-05 | 2.680E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 5.865E-05 | 2.863E-03 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 5.865E-05 | 2.863E-03 | AKR1B1, AKT1, EGFR, MMP2, MMP9 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 6.329E-05 | 3.069E-03 | ABL1, AKR1B1, AKT1, ALOX12, ALOX15, ALOX5, AOX1, APP, AURKB, BLM, CA1, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, IDO1, LMNA, MAP2K1, MAPK1, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, TNKS, TNKS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 7.063E-05 | 3.377E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 7.871E-05 | 3.670E-03 | AKT1, AURKB, MAP2K1, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 8.302E-05 | 3.838E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 8.750E-05 | 3.928E-03 | GAA, MGAM |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 8.750E-05 | 3.928E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.750E-05 | 3.928E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 8.750E-05 | 3.928E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 8.750E-05 | 3.928E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 8.750E-05 | 3.928E-03 | GAA, MGAM |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 8.750E-05 | 3.928E-03 | ALOX12, ALOX15 |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 9.467E-05 | 4.224E-03 | ABL1, AKT1, HIF1A, KDR |
| MF | GO:0003824; catalytic activity | GO:0016614; oxidoreductase activity, acting on CH-OH group of donors | 9.916E-05 | 4.397E-03 | AKR1B1, AOX1, HSD17B1, HSD17B10, HSD17B2, XDH |
| BP | GO:0051179; localization | GO:2000641; regulation of early endosome to late endosome transport | 1.004E-04 | 4.417E-03 | MAP2K1, MAPK1, SRC |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.002E-04 | 4.417E-03 | EGFR, HSD17B1, IGF1R, PIK3R1, TTR |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.004E-04 | 4.417E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.035E-04 | 4.534E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0051179; localization | GO:0043269; regulation of ion transport | 1.168E-04 | 5.085E-03 | ABL1, AKT1, APP, CA2, CA7, CAMK2B, DAPK1, DRD4, MAOB, MMP9, NPSR1, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.314E-04 | 5.587E-03 | AKT1, EGFR, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 1.398E-04 | 5.888E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, IDO1, MPO, PLA2G1B |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.609E-04 | 6.673E-03 | AXL, CSNK2A1, DRD4, EGFR, ESR1, GSK3B, SRC, TP53 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 1.664E-04 | 6.870E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 1.695E-04 | 6.958E-03 | AURKB, CSNK2A1, NEK2, NEK6, TNKS |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.744E-04 | 7.018E-03 | EGFR, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.744E-04 | 7.018E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 1.744E-04 | 7.018E-03 | MAP2K1, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.744E-04 | 7.018E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.744E-04 | 7.018E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 1.744E-04 | 7.018E-03 | GAA, MGAM |
| BP | GO:0009987; cellular process | GO:0014066; regulation of phosphatidylinositol 3-kinase signaling | 1.869E-04 | 7.459E-03 | EGFR, FLT3, KDR, MAPK1, PTK2 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.933E-04 | 7.626E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0044247; cellular polysaccharide catabolic process | 1.933E-04 | 7.626E-03 | GAA, MGAM, PYGL |
| BP | GO:0008152; metabolic process | GO:0009251; glucan catabolic process | 1.933E-04 | 7.626E-03 | GAA, MGAM, PYGL |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.990E-04 | 7.809E-03 | APP, BACE1, EGFR, KDR, MAPK1, NPC1, SRC, STAT6 |
| BP | GO:0022610; biological adhesion | GO:0051893; regulation of focal adhesion assembly | 2.116E-04 | 8.211E-03 | ABL1, KDR, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.116E-04 | 8.211E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 2.272E-04 | 8.710E-03 | CDK1, EGFR, IGF1R, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.554E-04 | 9.671E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.589E-04 | 9.786E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.261E-20 | 1.547E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.092E-14 | 2.589E-11 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.454E-13 | 9.046E-11 | ALPI, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, DNMT1, ESR1, ESR2, ESRRA, ESRRB, GLO1, L3MBTL1, MMP12, MMP13, MMP2, MMP3, MMP9, PARP1, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.933E-19 | 3.770E-17 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.910E-15 | 9.662E-13 | CAMK2B; MAP2K1; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; EGFR; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.731E-11 | 1.421E-09 | GSK3B; MAP2K1; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PTK2; IGF1R; ABL1; AKT1; MAPK1; MET; TP53 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.937E-11 | 1.421E-09 | CAMK2B; GSK3B; MAP2K1; SRC; ABL1; AKT1; MAPK1; PIK3R1; EGFR; PTK2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.643E-11 | 1.421E-09 | MAP2K1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53; EGFR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.086E-10 | 3.024E-09 | MAP2K1; SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; EGFR; ESR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.096E-11 | 2.306E-09 | MAP2K1; FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.382E-10 | 3.369E-09 | GSK3B; MAP2K1; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.919E-10 | 1.544E-08 | DNMT1; MAOB; PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; HSD17B1; ALOX5; HSD17B2; CD38; AOX1; XDH; MGAM; GAA; CYP2C9; CYP2C8; TBXAS1; CYP1A2; CYP1A1; ALPI; IDO1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.728E-10 | 8.077E-09 | CYP2C9; APP; CYP2C8; MAP2K1; MAOB; MAOA; ALOX5; ALOX15; MAPK1; ALOX12 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.590E-10 | 1.700E-08 | GSK3B; MAP2K1; AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.735E-09 | 2.603E-08 | CAMK2B; MAP2K1; AKT1; MAPK1; PIK3R1; TP53; EGFR; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.564E-09 | 4.633E-08 | MAP2K1; AKT1; MAPK1; PIK3R1; TP53; MET; EGFR; IGF1R |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.412E-09 | 6.595E-08 | MAP2K1; DNMT1; ABCC1; MMP9; EGFR; NFKB1; CDC25B; PIM1; ABL1; CYP1B1; MAPK1; TP53; MET |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.564E-09 | 4.633E-08 | CAMK2B; MAP2K1; AKT1; MAPK1; PIK3R1; HIF1A; EGFR; NFKB1; IGF1R |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.451E-09 | 2.359E-08 | MAOB; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1; IDO1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 9.247E-09 | 9.490E-08 | GSK3B; MAP2K1; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; EGFR; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.793E-08 | 2.094E-07 | GSK3B; MAP2K1; PIK3R1; PTK2; EGFR; NFKB1; IGF1R; KDR; AKT1; MAPK1; PKN1; TP53; MET |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.190E-08 | 1.105E-07 | GSK3B; MAP2K1; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.379E-08 | 1.223E-07 | CAMK2B; GSK3B; MAP2K1; ABL1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.450E-09 | 8.455E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.089E-08 | 2.162E-07 | MAP2K1; PLA2G1B; KDR; ABL1; AKT1; MAPK1; PIK3R1; MET; EGFR; NFKB1; IGF1R |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.893E-09 | 9.645E-08 | GSK3B; MAP2K1; AKT1; MAPK1; PIK3R1; TP53; EGFR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.686E-08 | 1.429E-07 | ALK; MAP2K1; AKT1; MAPK1; PIK3R1; TP53; EGFR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.913E-08 | 1.555E-07 | MAP2K1; FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.614E-08 | 4.640E-07 | MAP2K1; SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.104E-08 | 2.162E-07 | MAP2K1; SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.423E-08 | 3.525E-07 | MAP2K1; AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.425E-07 | 4.022E-06 | MAP2K1; PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 6.255E-07 | 3.485E-06 | GSK3B; MAP2K1; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.167E-08 | 1.690E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.101E-07 | 6.506E-07 | MAP2K1; ABL1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.484E-08 | 2.343E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; TBXAS1; ALOX12 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.538E-07 | 2.603E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.416E-08 | 4.640E-07 | CYP2C9; CYP2C8; MAOB; MAOA; CYP1A2; AOX1; CYP3A4 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 8.398E-07 | 4.426E-06 | MAP2K1; CDK1; AKT1; MAPK1; PIK3R1; CDC25B; IGF1R |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.709E-06 | 8.130E-06 | MAP2K1; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; EGFR; IGF1R |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.805E-09 | 8.455E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.835E-06 | 8.518E-06 | MAP2K1; MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.286E-06 | 1.424E-05 | MAP2K1; ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.137E-05 | 4.348E-05 | GSK3B; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.528E-06 | 3.058E-05 | GSK3B; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.499E-06 | 2.697E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.780E-07 | 4.506E-06 | GSK3B; MAP2K1; AKT1; MAPK1; PIK3R1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.321E-06 | 1.052E-05 | GSK3B; MAP2K1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.276E-06 | 6.220E-06 | MAP2K1; AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 9.992E-06 | 3.897E-05 | GSK3B; MAP2K1; ESRRB; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.534E-05 | 5.645E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.419E-06 | 3.351E-05 | CAMK2B; MAP2K1; SRC; MMP2; MAPK1; EGFR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.165E-06 | 5.824E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; AOX1; CYP3A4 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.001E-05 | 7.094E-05 | CAMK2B; MAP2K1; SRC; CD38; MAPK1; PIK3R1; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.534E-05 | 5.645E-05 | MAP2K1; AKT1; MAPK1; PIK3R1; HIF1A; EGFR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.515E-06 | 1.114E-05 | CSNK2A1; SRC; MAPK1; MET; EGFR; IGF1R |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.814E-05 | 6.550E-05 | GSK3B; MAP2K1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.595E-06 | 1.948E-05 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.682E-05 | 2.775E-04 | CAMK2B; MAP2K1; AKT1; MAPK1; PIK3R1; NFKB1; TSHR |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 6.118E-05 | 2.022E-04 | CAMK2B; GSK3B; MAOB; MAOA; AKT1; DRD4 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.045E-04 | 3.135E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 7.251E-05 | 2.356E-04 | MAP2K1; AKT1; MAPK1; PIK3R1; EGFR; IGF1R |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 9.258E-05 | 2.866E-04 | GSK3B; MAP2K1; AKT1; MAPK1; PIK3R1; PYGL |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.125E-04 | 3.323E-04 | MAP2K1; CXCR1; AKT1; MAPK1; PIK3R1; EGFR |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.868E-04 | 5.356E-04 | THPO; PIM1; AKT1; AOX1; STAT6; PIK3R1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.240E-04 | 8.538E-04 | GSK3B; MAP2K1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.412E-04 | 6.817E-04 | MAP2K1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.971E-04 | 9.927E-04 | MAP2K1; AKT1; MAPK1; TP53; EGFR; NFKB1; CDC25B |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.746E-04 | 7.543E-04 | GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.988E-04 | 7.982E-04 | CAMK2B; MAP2K1; AKT1; MAPK1; PIK3R1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.373E-04 | 3.996E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.006E-05 | 2.832E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.005E-04 | 3.061E-04 | MAP2K1; SRC; CDK1; MAPK1; EGFR |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.905E-05 | 1.011E-04 | CXCR1; SRC; MET; EGFR; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.099E-05 | 1.378E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.583E-05 | 1.226E-04 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 4.618E-04 | 1.120E-03 | SRC; TBXAS1; AKT1; MAPK1; PIK3R1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.963E-04 | 9.927E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 9.341E-04 | 2.047E-03 | MAP2K1; SRC; MAPK1; PIK3R1; PTK2; EGFR |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.793E-04 | 1.140E-03 | CAMK2B; MAP2K1; CDK1; MAPK1; IGF1R |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.611E-04 | 1.499E-03 | MAP2K1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.461E-03 | 4.896E-03 | CXCR1; SRC; KDR; MET; EGFR; IGF1R |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.974E-04 | 1.169E-03 | GSK3B; ABL1; CDK1; TP53; CDC25B |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.414E-03 | 4.852E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 5.547E-04 | 1.273E-03 | GSK3B; ABL1; MAPK1; MET; PTK2 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.757E-03 | 5.376E-03 | CXCR1; THPO; FLT3; KDR; MET; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.935E-03 | 4.014E-03 | BACE1; APP; GSK3B; MAPK1; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.488E-03 | 4.901E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.775E-03 | 3.762E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.911E-03 | 4.008E-03 | CAMK2B; GSK3B; MAP2K1; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.464E-03 | 3.171E-03 | MAP2K1; AKT1; MAPK1; PIK3R1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 7.727E-03 | 1.345E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 6.694E-03 | 1.187E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 8.281E-03 | 1.429E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.206E-03 | 4.481E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 1.473E-02 | 2.354E-02 | MAP2K1; MAOB; MAOA; MAPK1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.167E-02 | 1.945E-02 | MAP2K1; AKT1; MAPK1; PIK3R1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.643E-02 | 2.563E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.481E-03 | 6.591E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 3.426E-02 | 4.876E-02 | MAP2K1; MAPK1; PIK3R1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 4.513E-04 | 1.114E-03 | MAP2K1; AKT1; MAPK1; PIK3R1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.760E-02 | 4.047E-02 | AKT1; PIK3R1; IGF1R |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.790E-04 | 7.557E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.537E-02 | 3.805E-02 | MAP2K1; PLA2G1B; MAPK1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.616E-02 | 2.542E-02 | CAMK2B; AKT1; PYGL |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.574E-02 | 2.495E-02 | PIK3R1; NFKB1; PTK2 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 7.593E-04 | 1.702E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.412E-02 | 2.294E-02 | CA2; PLA2G1B; CD38 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.297E-02 | 2.125E-02 | CSNK2A1; PARP1; NFKB1 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.117E-02 | 1.878E-02 | THPO; FLT3; CD38 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.050E-02 | 1.780E-02 | MAPK1; PKN1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.797E-04 | 9.742E-04 | SRC; ABL1; MAPK1; NFKB1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 5.063E-03 | 9.226E-03 | CAMK2B; MAP2K1; MAPK1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 5.280E-03 | 9.533E-03 | CAMK2B; MAOB; MAOA |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.644E-03 | 8.544E-03 | AKT1; PIK3R1; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.185E-03 | 6.089E-03 | AKT1; PIK3R1; TSHR |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 3.873E-03 | 7.192E-03 | MAP2K1; MAPK1; IGF1R |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 3.385E-02 | 4.854E-02 | GSK3B; TP53 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 3.185E-03 | 6.089E-03 | MGAM; GAA; PYGL |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 2.840E-02 | 4.133E-02 | MAOB; MAOA |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.174E-03 | 4.462E-03 | MAOB; MAOA; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.633E-02 | 3.889E-02 | MAPK1; PIK3R1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.700E-03 | 3.643E-03 | MGAM; AKT1; PIK3R1 |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 2.633E-02 | 3.889E-02 | AOX1; HSD17B10 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.432E-02 | 3.676E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.238E-02 | 3.409E-02 | ABCC1; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.783E-02 | 2.759E-02 | MAPK1; PIK3R1 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.451E-02 | 2.339E-02 | MAP2K1; MAPK1 |
| hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 1.870E-02 | 2.872E-02 | MAOB; MAOA |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 3.752E-04 | 9.742E-04 | MAP2K1; MAPK1; EGFR |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.652E-04 | 1.120E-03 | MAP2K1; MAPK1; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.149E-04 | 1.195E-03 | MGAM; GAA; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.297E-02 | 2.125E-02 | POLB; PARP1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 8.144E-04 | 1.805E-03 | MAOB; MAOA; AOX1 |
| hsa00760 | Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | 1.011E-02 | 1.729E-02 | AOX1; CD38 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.428E-03 | 1.150E-02 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 6.988E-03 | 1.228E-02 | MAOB; MAOA |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 3.527E-03 | 6.613E-03 | MAOB; MAOA |
| hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 3.109E-02 | 4.491E-02 | AOX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.702E-04 | 7.527E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; DNMT1; DNMT1; AURKB; TP53; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ESR1; APP |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| NA: NA | Edema | NA | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; DNMT1; IGF1R; IGF1R; EGFR; EGFR; KDR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | MAOB |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; DNMT1; KDR |
| NA: NA | Motor symptoms | NA | MAOB |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; MMP2; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A; EGFR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1; SRC |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; CD38; AURKB; TP53 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ABL1; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; PTK2; TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAOB |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; PARP1 |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; PARP1; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; IGF1R; CDK1; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | IDO1; MAOB; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; EGFR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOB; MAOB; MAOA |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; IDO1; CSNK2A1; CDC25B; FLT3; FLT3; CA9; ABL1; MMP2; DNMT1; SRC; IGF1R; CD38; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; EGFR; PIM1; PARP1; PTK2; TP53; ESR1; ESR1; CA1; KDR; APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM; KDR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; SRC; EGFR; EGFR |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR; KDR; APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESRRA; MMP2; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; EGFR; EGFR; PARP1; KDR; KDR; KDR; KDR |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; KDR; KDR |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAOB |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; EGFR; EGFR; EGFR; ESR1; ESR1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR; ESR1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53; KDR; KDR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM; NFKB1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; FLT3; CA9; ABL1; MMP2; SRC; IGF1R; AURKB; HIF1A; MAPK1; MMP9; EGFR; PTK2; TP53; KDR; KDR; KDR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOB; MAOA; MAOA |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ESRRA; ALOX5; MMP3; CAMK2B |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; MAOB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAOB |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; PLA2G1B; ESRRA; ALOX5; ALOX5; MMP12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOB; CYP3A4; MAOA |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; TP53; KDR |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAOB; MAOA; APP |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; ABL1; EGFR; ESR1 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |